e2-Capital makes strides in building biotech business

e2-Capital wins three mandates to provide advisory and fundraising services to Chinese biotech projects.

Five months after announcing plans to develop a biotechnology business, Hong Kong-based technology banking group e2-Capital is beginning to put its money where its mouth is.

The company, along with six other investors, has chipped in HK$5 million $640,000 for a 6.5% stake in ChipScreen BioScience, a HK$76 million drug-screening joint venture with Beijing-based Tsing Hua University. The biggest investor, with a nearly 19% stake, is Hong Kong's New World Development real estate group.


FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Click for more on: e2capital | makes | strides | building | biotech | business

Print Edition

FinanceAsia Print Edition